Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

Evotec AG (Frankfurt Stock Exchange: EVT) Reported Today Results for the First Nine Months of 2007.

HAMBURG, Germany and OXFORD, England, November 13 /PRNewswire-FirstCall/ --

Highlights:

- Financials in-line with Evotec's full year expectations

- Compelling results achieved in two proof-of-concept Phase II trials with lead insomnia drug candidate EVT 201

- Sale of the Chemical Development Business to Aptuit and the proposed Renovis acquisition further emphasize the strategic transformation of Evotec towards a drug discovery and development company

- Merger will create a global company with three clinical candidates, a strong late stage preclinical pipeline focusing on areas of neurological and inflammatory diseases, and a strong cash position; expected to close in Q1 2008

- Expected year-end cash position increased to EUR 93-98 million, not yet including Renovis' cash

All amounts discussed in this press release are related to Evotec's continuing operations. The discontinued operations and a discussion of the business sold to Aptuit are provided in Evotec's full Third Quarter Report.

Revenues for the first nine months of 2007 were EUR 23.2 million, 23% below last year's level (2006: EUR 29.9 million). The decline is the consequence of (i) lower milestone income compared to the same period last year (approximately - EUR 3 million), (ii) the reduction of the library synthesis business following the transfer of this business into a joint venture with RSIL (reduction of EUR 4.0 million or 82%), and (iii) decline of the US dollar against Evotec's reporting currency Euro. At constant 2006 currencies (UK Sterling and US dollar), revenues would have been approximately one million higher (EUR 24.1 million). Excluding these three extraordinary effects Evotec's remaining business performed strongly, growing 6% from EUR 21.9 million for the first nine months of 2006 to EUR 23.2 million for the first nine months 2007.<
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 Protea ... AG jointly announced today an update from their ... 3D InSight™ microtissues. In August 2014, Protea received ... scientific team for onsite training on the handling ... developed workflows for processing the 3D microtissues for ...
(Date:10/2/2014)... Wayne, NJ (PRWEB) October 02, 2014 At ... squeezed, Bel-Art Products has introduced a new kind ... New to market is the Scienceware® Squeeze Rite™ Wash ... the dip tube position within the bottle reduces the waste ... complete dispensing of those liquids. , “Easier to squeeze when ...
(Date:10/2/2014)... 2, 2014  CSSi ( www.CSSiEnroll.com ), the ... research industry, is pleased to announce its participation ... of October.  President Chris Trizna will ... in Clinical Trials New England conference sponsored by ... the annual Site Solutions Summit sponsored by the ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , Oct. 2, ... a leader in synthetic biology, and Amneal ... manufacturer by volume in the U.S., today announced ... (ECC) for a target active pharmaceutical ingredient (API).  ... of the collaboration is to develop a consistent, ...
Breaking Biology Technology:Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 3Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 4New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3
... Aug. 28 Medivation, Inc.,(Nasdaq: MDVN ) today ... will present at the following conferences:, -- BioCentury,s ... 9:00 a.m. Eastern Time at the Millennium Broadway Hotel ... Conference on Wednesday, September 24,at 4:30 p.m. Eastern Time ...
... Exclusion of Venous Thromboembolism-, LEXINGTON, Mass., Aug. ... US Food and Drug Administration (FDA) has,granted 510(k) ... HemosIL D-Dimer,assay to exclude venous thromboembolism (VTE) in ... embolism (PE), when used in,conjunction with a clinical ...
... (ESA) has appointed the UK,s National Physical Laboratory (NPL) ... will lead a consortium to identify the next generation ... in future space missions. , "Advances in nanotechnology are ... Research Scientist in the nanomaterials group at NPL, who ...
Cached Biology Technology:Medivation Announces Participation in Upcoming Conferences 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... Prenatal exposure to tetrachloroethylene (PCE) in drinking water ... abruption, according to a new study led by ... , The study, published in the journal ... 1,019 unexposed pregnancies among 1,766 women in Cape ... late 1960s to the early 1980s by the ...
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... Autism Speaks applauds the consensus statement and recommendations ... disorders in children with autism spectrum disorders (ASD) released ... advancing physician awareness of unique challenges in the medical ... see the publication of these consensus recommendations. Autism Speaks, ...
... nerves are the likely origin of the Devil Facial Tumour ... an international team of scientists has discovered. Devil ... only Tasmanian devils and was first reported in 1996. It ... disease is characterised by large tumours, mostly on the face ...
... have new insight into the sex lives of the much-maligned ... deaths, according to a report published online on December 31st ... finding a partner of the right species type, male and ... harmony. Those tones are produced and varied based on the ...
Cached Biology News:Pediatrics GI recommendations -- first step to guidelines for children with autism 2Pediatrics GI recommendations -- first step to guidelines for children with autism 3Nervous culprit found for Tassie devil facial tumor disease 2To a mosquito, matchmaking means 'singing' in perfect harmony 2
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: